Related Experiment Video
Updated: Jan 13, 2026

High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia
Published on: January 19, 2022
MIS-C: Diagnosis, Management, and Outcomes
Christophe El Rassi1, Roy El Darzi1, Maria Abou Mansour1
1Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Insights
Multisystem inflammatory syndrome in children (MIS-C) is a severe post-COVID-19 condition. Early diagnosis and management, including immunomodulation and thromboprophylaxis, are crucial for better outcomes.
Area of Science:
- Pediatrics
- Infectious Diseases
- Immunology
Background:
- Multisystem inflammatory syndrome in children (MIS-C) is a serious post-COVID-19 condition.
- It presents with fever, shock, and multiorgan involvement, particularly cardiovascular issues.
Purpose of the Study:
- To review current evidence on MIS-C epidemiology, pathophysiology, and clinical presentation.
- To emphasize MIS-C diagnosis, management strategies, and differentiation from similar conditions.
Main Methods:
- Comprehensive literature review of MIS-C.
- Synthesis of data on diagnosis, treatment, and complications.
Main Results:
- MIS-C management involves supportive care, hemodynamic stabilization, and immunomodulation (IVIG, steroids, biologics).
- Thromboprophylaxis is often needed due to high thromboembolic risk.
- Long-term follow-up is vital for potential cardiac, GI, and neurological issues.
Conclusions:
- Effective MIS-C management requires distinguishing it from similar syndromes.
- Challenges remain in diagnostic clarity and standardized treatment protocols.
- Despite progress, ongoing research is needed for optimal patient care.
Abstract:
Multisystem inflammatory syndrome in children (MIS-C) is an emergent postinfectious hyperinflammatory disorder predominantly affecting the pediatric population following COVID-19 infection. Clinically, it is characterized by persistent fever, shock, multiorgan involvement, and potentially severe cardiovascular involvement. This comprehensive review synthesizes current evidence on the epidemiology, pathophysiology, clinical presentation, diagnostic criteria, with particular emphasis on the management of MIS-C. We also stress on the importance of distinguishing MIS-C from phenotypically similar entities. Acute-phase management centers on supportive care, hemodynamic stabilization, and targeted immunomodulation, with intravenous immunoglobulin, corticosteroids, and biologic forming the therapeutic cornerstone. Thromboprophylaxis is frequently warranted due to the elevated thromboembolic risk, and long-term follow-up is essential to monitor for cardiac, gastrointestinal, and neurologic complications. Additional considerations include postrecovery vaccination protocols and the use of extracorporeal membrane oxygenation in cases of refractory cardiorespiratory failure. Despite advancements in clinical outcomes, diagnostic ambiguity and heterogeneous management guidelines continue to pose significant challenges.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Mitral Valve Prolapse II: Assessment and Management
Documentation of Nursing Diagnosis
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...
Mitral Valve Prolapse III: Nursing Management
Mitral Stenosis III: Medical Management
